Dr. Dominic Paul Amara, M.D. Obstetrics & Gynecology Medicare: May Accept Medicare Assignments Practice Location: 181 Andrieux St, Suite108, Sonoma, CA 95476 Phone: 707-938-3300 Fax: 707-938-2315 |
News Archive
A new study shows methamphetamine's potential lasting behavioral effects on kids of mothers who used meth during pregnancy. The behavior differences — anxiety, depression, moodiness — weren't huge, but lead researcher Linda LaGasse called them "very worrisome."
Royal Philips Electronics today introduced the Juno DRF and the DigitalDiagnost - ER Wireless systems, two versatile diagnostic X-ray solutions that represent the next step in patient care. Featured at the 96th annual meeting of the Radiological Society of North America (RSNA) in Chicago, these innovative systems uphold Philips' commitment to integrating technologies in a smart way to help enhance patient outcomes and increase value for healthcare systems.
Climate change could kill more than 500000 adults in 2050 worldwide due to changes in diets and bodyweight from reduced crop productivity, according to new estimates published in The Lancet. The research is the strongest evidence yet that climate change could have damaging consequences for food production and health worldwide.
The Salt Lake Tribune: "Utah's Medicaid program isn't providing enough oversight of its managed care plans, a problem that is costing the state as much as $19 million, according to a Legislative audit released Tuesday" (Rosetta, 1/19).
Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND). The first center at which the drug will be evaluated is Emory University under the direction of Dr. Hyder A. Jinnah, MD, PhD. The study is designed to evaluate the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with LND.
› Verified 8 days ago